A detailed history of Raymond James Financial Inc transactions in Bio Affinity Technologies, Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 500 shares of BIAF stock, worth $1,305. This represents 0.0% of its overall portfolio holdings.

Number of Shares
500
Holding current value
$1,305
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

BUY
$0.2 - $1.09 $100 - $545
500 New
500 $0

Others Institutions Holding BIAF

About bioAffinity Technologies, Inc.


  • Ticker BIAF
  • Exchange
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 2,727,580
  • Market Cap $7.12M
  • Description
  • bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is b...
More about BIAF
Track This Portfolio

Track Raymond James Financial Inc Portfolio

Follow Raymond James Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Inc with notifications on news.